<DOC>
	<DOCNO>NCT00975767</DOCNO>
	<brief_summary>The main purpose study assess safety profile MGCD265 administer combination market anticancer drug erlotinib docetaxel .</brief_summary>
	<brief_title>A Study MGCD265 Given With Erlotinib Docetaxel Subjects With Advanced Malignancies Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Part 1 : Patients advance metastatic unresectable solid malignancy refractory standard therapy and/or exist therapy . Evaluable disease . Documented progressive disease follow recent treatment regimen . Adequate hepatic parameter . Age ≥18 year . Life expectancy great 3 month . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Adequate renal function . Adequate bone marrow function . Capable understand comply protocol write informed consent . Negative pregnancy test woman childbearing potential . Use adequate contraception need . Subjects consent optional fresh biopsy , must require concurrent anticoagulation medication . Part 2 : Histologically cytologically confirm advanced Stage 3b 4 NSCLC . Measurable disease per RECIST . At least one prior chemotherapy regimen advance disease . No prior erlotinib docetaxel therapy . Documented progressive disease follow recent treatment regimen . Adequate hepatic parameter . Age ≥18 year . Life expectancy great 3 month . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Adequate renal function . Adequate bone marrow function . Capable understand comply protocol write informed consent . Negative pregnancy test woman childbearing potential . Use adequate contraception need . Recent anticancer treatment . Prior treatment investigational cmet inhibitor HCF inhibitor antibody . Uncontrolled concurrent illness . History bleed diathesis coagulopathy . History stroke transient ischemic attack . History cardiovascular illness . QT interval correct heart rate ( QTc ) &gt; 470 msec . Left ventricular ejection fraction ( LVEF ) &lt; 50 % . Immunocompromised subject . Lack recovery grade ≤1 significant adverse event due antineoplastic agent , investigational drug , medication administer prior study enrollment . Symptomatic uncontrolled brain metastasis require current treatment . Active gastrointestinal condition history abdominal fistula , gastrointestinal perforation intraabdominal abscess . History malignancy treat curative intent within 5 previous year . Lung tumor lesion increase likelihood bleeding . History major surgery within 28 day first receipt study drug . History autologous bone marrow transplant ( BMT ) within previous five year , subject organ transplant allogeneic BMT . Nursing pregnant woman ; female subject childbearing potential must negative pregnancy test screening . Unable swallow oral medication preexist gastrointestinal disorder might interfere proper absorption oral drug . Any condition find opinion Investigator Medical Monitor may render subject excessive risk treatment complication may render difficult evaluation treatment response . Allergy hypersensitivity component either MGCD265 , erlotinib docetaxel formulation ( depend group subject assign ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>